Promising new combo therapy targets Hard-to-Treat lymphoma

NCT ID NCT02180711

Ongoing Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a drug called acalabrutinib, alone or together with other drugs (rituximab and lenalidomide), in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see how safe these combinations are and whether they can shrink tumors. About 113 adults are taking part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

acalabrutinib (a targeted cancer drug) alone or combined with rituximab and lenalidomide

What this could lead to

If successful, this could provide a new treatment option for people with certain types of non-Hodgkin lymphoma that have not responded to prior therapy.

What could go wrong

This is an early-phase trial with a small number of participants, so results may not apply broadly. Side effects from the drug combinations are possible and being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Locations

Research Site

Tucson, Arizona, 85719, United States
Research Site

Downey, California, 90241, United States
Research Site

Duarte, California, 91010, United States
Research Site

Fountain Valley, California, 92708, United States
Research Site

Santa Monica, California, 90404, United States
Research Site

Coral Gables FL, Florida, 33146, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Chicago, Illinois, 60612, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Louisville, Kentucky, 40207, United States
Research Site

New Orleans, Louisiana, 70112, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Morristown, New Jersey, 07960, United States
Research Site

Hawthorne, New York, 10532, United States
Research Site

Lake Success, New York, 11042, United States
Research Site

New York, New York, 10021, United States
Research Site

Syracuse, New York, 13210, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Greenville, South Carolina, 29615, United States
Research Site

Dallas, Texas, 75235, United States
Research Site

Houston, Texas, 77030, United States
Research Site

San Antonio, Texas, 78217, United States
Research Site

Temple, Texas, 76508, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Spokane, Washington, 99208, United States
Research Site

Waukesha, Wisconsin, 53188, United States
Research Site

Edmonton, Alberta, t6G1Z2, Canada
Research Site

London, Ontario, N6A 5W9, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Bologna, 40138, Italy
Research Site

Milan, 20132, Italy
Research Site

Palermo, 90146, Italy